New phase 3 results from four trials suggest faricimab could offer increased treatment intervals for patients with wet age-related macular degeneration or diabetic macular edema, according to a press release from Genentech.
Results showed faricimab, when administered at intervals of up to 4 months, offered noninferior vision gains compared with aflibercept administered every 2 months, the release said.
“These positive results show the potential for faricimab as the first new type of medicine in 15 years for people with neovascular age-related macular degeneration and in close to a decade
Uncategorized